TRCT
KALV

Tower Research Capital (TRC)’s KalVista Pharmaceuticals KALV Stock Holding History

Tower Research Capital (TRC)’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51K Buy
2,534
+2,164
+585% +$34.9K ﹤0.01% 2724
2025
Q4 		$5.97K Sell
370
-2,515
-87% -$33.3K ﹤0.01% 4089
2025
Q3 		$35.1K Sell
2,885
-5,174
-64% -$71.5K ﹤0.01% 2802
2025
Q2 		$91.1K Buy
8,059
+7,180
+817% +$87.8K ﹤0.01% 2458
2025
Q1 		$10.1K Sell
879
-5,448
-86% -$55.6K ﹤0.01% 3672
2024
Q4 		$53.6K Buy
6,327
+5,502
+667% +$57K ﹤0.01% 2506
2024
Q3 		$9.55K Sell
825
-2,866
-78% -$36K ﹤0.01% 3857
2024
Q2 		$43.5K Buy
3,691
+3,525
+2,123% +$41.1K ﹤0.01% 3208
2024
Q1 		$1.97K Sell
166
-3,316
-95% -$44.2K ﹤0.01% 5149
2023
Q4 		$42.7K Buy
3,482
+768
+28% +$6.99K ﹤0.01% 3238
2023
Q3 		$26.1K Buy
2,714
+874
+48% +$8.93K ﹤0.01% 3138
2023
Q2 		$16.6K Buy
1,840
+806
+78% +$7.43K ﹤0.01% 3553
2023
Q1 		$8K Sell
1,034
-1,258
-55% -$9.39K ﹤0.01% 4638
2022
Q4 		$15K Buy
2,292
+338
+17% +$1.81K ﹤0.01% 3424
2022
Q3 		$29K Sell
1,954
-165
-8% -$2.31K ﹤0.01% 3624
2022
Q2 		$21K Sell
2,119
-69
-3% -$761 ﹤0.01% 3744
2022
Q1 		$32K Buy
2,188
+1,501
+218% +$21.6K ﹤0.01% 3086
2021
Q4 		$9K Sell
687
-178
-21% -$2.83K ﹤0.01% 4700
2021
Q3 		$15K Sell
865
-5,736
-87% -$116K ﹤0.01% 3982
2021
Q2 		$158K Buy
6,601
+2,917
+79% +$76.3K ﹤0.01% 2093
2021
Q1 		$95K Buy
3,684
+10
+0.3% +$263 ﹤0.01% 2629
2020
Q4 		$70K Sell
3,674
-11,297
-75% -$194K ﹤0.01% 2722
2020
Q3 		$188K Buy
14,971
+1,312
+10% +$16.4K ﹤0.01% 2629
2020
Q2 		$165K Buy
+13,659
New +$145K 0.01% 1971
2019
Q4 		– Sell
-3,877
Closed -$45K – 3952
2019
Q3 		$45K Buy
3,877
+3,685
+1,919% +$59.5K ﹤0.01% 1864
2019
Q2 		$4K Buy
192
+158
+465% +$3.71K ﹤0.01% 3029
2019
Q1 		$1K Sell
34
-128
-79% -$2.77K ﹤0.01% 3575
2018
Q4 		$4K Sell
162
-1,580
-91% -$31.8K ﹤0.01% 3043
2018
Q3 		$39K Buy
1,742
+1,414
+431% +$19.1K ﹤0.01% 1919
2018
Q2 		$3K Sell
328
-953
-74% -$8.41K ﹤0.01% 3232
2018
Q1 		$12K Buy
1,281
+441
+53% +$4.62K ﹤0.01% 2395
2017
Q4 		$8K Buy
+840
New +$8.74K ﹤0.01% 2668
2017
Q3 		– Sell
-905
Closed -$7K – 3982
2017
Q2 		$7K Buy
905
+200
+28% +$1.47K ﹤0.01% 1816
2017
Q1 		$6K Buy
705
+442
+168% +$3.32K ﹤0.01% 2098
2016
Q4 		$2K Sell
263
-486
-65% -$3.58K ﹤0.01% 3424
2016
Q3 		$5K Sell
749
-1,170
-61% -$8.82K ﹤0.01% 2554
2016
Q2 		$18K Buy
+1,919
New +$22.2K ﹤0.01% 2327
2016
Q1 		– Sell
-24
Closed -$1K – 4545
2015
Q4 		$1K Sell
24
-98
-80% -$5.13K ﹤0.01% 4098
2015
Q3 		$6K Buy
+122
New +$10.4K ﹤0.01% 2664

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tower Research Capital (TRC)'s KALV Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its KalVista Pharmaceuticals (KALV) stake by 585% in Q1 2026, buying an estimated $34.9K and bringing the position to 2,534 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #2724.

Tower Research Capital (TRC) first reported a position in KALV in Q3 2015 and has held it in 39 quarters since. The position peaked at $188K in Q3 2020. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Tower Research Capital (TRC) held 2,534 shares of KalVista Pharmaceuticals worth $51K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,164 KalVista Pharmaceuticals shares in Q1 2026, an estimated $34.9K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2724 holding.
  • Tower Research Capital (TRC) first reported a position in KalVista Pharmaceuticals in Q3 2015 and has held it in 39 quarters since.
  • Tower Research Capital (TRC)'s KalVista Pharmaceuticals position peaked at $188K in Q3 2020.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.